Objective: To evaluate efficacy, safety and feasibility of targeted intracoronary injection using pro-urokinase combined with anisodamine (TCA) versus thrombus aspiration (TA) in ST-elevation myocardial infarction (STEMI) patients with high thrombus loads.
| INTRODUCTION
In primary PCI treatment for ST-elevation myocardial infarction (STEMI), severe thrombus load is very common in many infarct-related arteries (IRAs). 1 A high thrombus load (grade 3 or higher) not only directly occludes the IRA, but also generates thrombotic micro-debris to further obstruct the myocardial microcirculatory system. A quick, effective, and safe clearance of thrombosis in the IRA plays a key role in reperfusion treatment in STEMI patients with high thrombus loads.
Otherwise, it risk worsening the stenosis or causing re-occlusion in IRAs, and potentially extending the area of myocardial infarction and dysfunctional myocardial microcirculation, in turn resulting in severe complications such as acute heart failure, cardiac shock, and sudden death.
Vacuum aspiration via catheter is one effective approach to high thrombus loads, and is widely used in present PCI technique. However, recent prospective randomized clinical trials (such as the TASTE and TOTAL studies) have indicated that patients receiving thrombus aspiration techniques gained no benefit compared with those receiving regular PCI. 2, 3 What is more, thrombus aspiration appears to increase the risk of thrombus detachment and stroke.
The technique of targeted intracoronary thrombolysis is another approach for treatment of high coronary thrombus load. This approach is based on the mechanism of chemical disintegration and melting of thrombi, rather than suction or other mechanical manipulation of thrombi. Therefore, it averts distal obstruction of the myocardial microvascular system with consequent degradation of myocardial reperfusion. Promisingly, the new generation of thrombolytics such as pro-urokinase have a characteristic of high selectivity and rapid fibrolysis of coronary thrombi. 4, 5 Targeted intracoronary thrombolysis with these new-generation thrombolytics shows improved efficacy and safety in clearance of coronary thrombosis in several studies.
Anisodamine is a medicine with multiple pharmacologic mechanisms which can effectively improve microcirculatory perfusion in shock and frostbite and diminish ischemic reperfusion injury. 6 Our previous preclinical and clinical research on this medicine over 20 years indicates anisodamine is effective for clearing STEMI patients' myocardial microcirculation. [7] [8] [9] Especially for those with severe myocardial infarction, it can also increase mean coronary perfusion pressure, enhance tolerance for ischemia and anoxia, and maintain the stability of myocardial electrophysiology. These characteristics hold obvious potential benefit in the treatment of STEMI patients with high thrombus loads.
For these reasons, we designed this prospective randomized controlled trial to compare efficacy and safety between the strategy of targeted intracoronary thrombolysis with pro-urokinase combined with anisodamine via intracoronary injection, and the strategy of classic intracoronary thrombus aspiration, in order to explore a safer and more feasible and effective treatment in STEMI patients with high thrombus loads. After exclusion by the criteria, the enrolled patients were 1:1 randomized into the thrombolysis combined with anisodamine group (TCA group) or the thrombus aspiration group (TA group). During the following PCI, in the TA group, when we failed to appropriately place thrombus aspiration catheter to perform a successful aspiration, the patient would be transferred to TCA group and received intracoronary thrombolysis and anisodamine treatment. The patients of TCA group who was not able to receive a successful thrombolysis procedure for such as the thrombolysis catheter could not approach to the target thrombus or anisodamine injecting failure would be eliminated due to the thrombolytic already injected might disturb the result of the trial.
| MATERIALS AND METHODS

| Study population
Patients were selected, randomized, and followed up according to the flowchart given in Figure 1 .
All included subjects gave written, informed consent to the study, which was approved by the ethics committee of Second Hospital of Hebei Medical University. Two anisodamine injections were also sequentially performed using the above technique. The first injection was carried out at the time the thrombolytic was injected, and the second was at the end of the thrombolysis period, just before the final angiography. Each injection dose of anisodamine is 4 mg (4 mg:10 mL, Tianjin Pharmaceuticals, Tianjin, China).
| TA group
Routine coronary aspiration was performed in the TA group patients.
Using the Export AP aspiration catheter (Medtronic Cardiovascular, CA), 3-5 applications of vacuum suction with 60 mL volume per suction were performed over no more than 10 min. After that, we performed a second angiography to evaluate the result, and implanted stents if indicated.
| IMR examination
We used the arterial physiologic detector (RadiAnalyzer Xpress 
| 90-Day follow-up
All patients received routine medical therapy include dual antiplatelet treatment (Aspirin with Ticagrelor or Clopidogrel), β-blocker, and ACEI/ARB. By outpatient and telephone follow up, major adverse coronary events (MACEs) (cardiac death, reinfarction, and malignant arrhythmia, etc.) and bleeding complications were recorded. MACE occurrence at 90-day follow-up was defined as the secondary endpoint.
| Statistics method
All analyses were performed with the SPSS 20.0 software (IBM, Armonk, NY). Continuous variables were examined by Levene's method, then expressed as mean ± standard deviation (SD) and median (Q25%, Q75%), and categorical variables were reported as frequency n (%). Student's t or Fisher's test or Mann-Whitney U test was used when appropriate. p < 0.05 was considered statistically significant.
| RESULTS
After screening by the criteria of enrollment and exclusion (see Table 1 ), there was a total of 42 patients enrolled, and then divided During the primary PCI, two patients in the TA group were transferred to the TCA group because the aspiration catheter failed to arrive at appropriate position to launch an aspiration, while three patients in the TCA group were eliminated from the study because the microcatheter did not reach the target thrombus and fail to perform a successful intracoronary thrombolysis. Therefore, 20 patients were enrolled in TCA group while 19 patients in TA group at last. There were no statistical differences between the two groups in clinical characteristics such as age, sex, vital signs, risk factors, GRACE, and CRUSADE scores. Laboratory tests such as CK-MB, cTnI, serum creatine, potassium, and glucose also showed no significant differences (see Table 2 ).
When examining imaging features related to the initial CAG and PCI, such as onset-to-balloon time (Onset-B), and first-medical-contact-to-balloon time (FMC-B) for the IRA, there was no statistical difference. The initial TIMI flow grade, CTFC, and thrombus grade showed no discrepancy between the two groups either (see Table 3 )
Immediately after the reperfusion therapy, angiography showed that the TCA group had more patients reaching grade 3 TIMI flow (75.0% Table 4 ).
In the repeat CAG 7 days later, we discovered almost all of the Tables 5 and 6 ).
When a 90-day follow-up was concluded, we found no difference in incidence of MACEs or stroke. As to bleeding complications, there were no major bleeding events in either group, and no significant difference in occurrence rates of minor bleeding complications (20.0%
vs. 15.8%, p = 1.000) between the two groups (see Table 7 ).
| DISCUSSION
In STEMI, one of the most severe and critical cardiovascular emergencies, opening the IRA without delay to rescue surviving myocardium is the most important principle in therapeutics. Due to the pathophysiologic mechanism of STEMI, the magnitude of coronary thrombus directly relates to the severity of the myocardial infarction, the risk of cardiac death, and the difficulty of reperfusion therapies, as well as the final prognosis of this disease. 11 In particular, for those with grade Refuse to enroll into study 3
Contraindication of anti-coagulation 2
Total 88
Abbreviations: IRA, infarct related artery; PCI, percutaneous coronary intervention. Since the 1980s, directly injecting thrombolytic medicine via catheters into coronary arteries has been undertaken, and its feasibility has been verified through serial studies. 12, 13 In clinical practice, selective intracoronary thrombolysis has been an effective method to treat high thrombus loads in coronary arteries. Particularly after the appearance of today's new generation of highly selective thrombolytics, intracoronary thrombolysis is found more and more to have vessel-opening benefits and to show high safety. 5, [11] [12] [13] [14] In this study, for STEMI patients with grade 3 or higher thrombus load, after treating by targeted intracoronary thrombolysis combined with anisodamine, the thrombosis in epi- In the TA group, even customary thrombus aspiration rapidly cleared the severe thrombosis and re-opened the IRA. However, comparing with the TCA group, there were still many residual thrombosis in the arteries after aspiration was performed, and longer perfusion time and lower perfusion level. To explain these results, we hypothesize that aspiration's mechanical and physical squeezing and dismembering of the thrombosis might cause secondary generation of micro-debris to obstruct the prearteriolar and arteriolar vessels, which then affects the perfusion of entire microcirculation system.
In addition, the vacuum suction mechanism briefly decreases the vol- the injection of thrombolytic medicine can easily reach a considerable local concentration and make full-scale contact with the surface of the thrombosis. In some of our cases, we even directly stabbed into the core area of thrombosis and performed a thrombolysis, resulting in rapid and effective disintegration and "melting" of the heavy thrombus load. Second, intracoronary targeted injection can ablate not only the gross thrombosis in epicardial vessels, but the thrombolytic particles can also readily reach the most microscopic parts of the structure of the coronary circulatory system, and then utterly melt down all micro thrombosis and debris. This characteristic may eventually achieve a permeating clearance to the thrombosis, extending from the conductive vessels to the arteriolar vessels.
Another explanation for our good outcomes is that we chose the third-generation highly selective thrombolytic pro-urokinase as our intracoronary thrombolytic medicine. Compared with the older generation thrombolytics, like urokinase and streptokinase, it does not conjugate with plasma prothrombin, which avoids the dose waste before contact with the thrombosis, and refrains from stimulating the coagulatory system to produce additional thrombus before performing its anti-thrombotic effect, as well as reducing the incident rate of bleeding events. Therefore, we selected this drug for its more effective thrombus ablation and higher safety profile. Abbreviations: MACE, major adverse cardiovascular events; TCA, thrombolysis and anisodamine via catheter; TA, thrombus aspiration; TVR, target vessel revascularization.
perfusion, and it has additional benefits of preventing deterioration and improving function in the myocardial microcirculation, increasing the level of myocardial reperfusion, decreasing the area of infarction, and further meliorating the prognosis.
